Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-04-27

Vor Biopharma (VOR)

CEO Jean-Paul Kress was paid $65,027,569 in fiscal year 2025 (SEC filing 0001193125-26-181883 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$65,027,569
Jean-Paul Kress total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
—
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Jean-Paul Kress (President, Chief Executive Officer and Chairman), FY2025 total compensation $65,027,569 (base salary $344,615) [exec_comp, SEC accession 0001193125-26-181883, filed 2026-04-27]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

VOR's next annual pay disclosure, estimated May 16, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Jean-Paul Kress$344,615$400,000$0$64,013,465$251,425$0$18,064$65,027,569
President, Chief Executive Officer and Chairman
Sandesh Mahatme217,846274,00035,262,1853,540,099102,99608,97239,406,098
Chief Financial Officer
Qing Zuraw243,385100,0002,230,2508,570,85200692,70611,837,193
Former Chief Development Officer
Robert Ang515,0260184,2501,176,895001,488,2243,364,395
Former President and Chief Executive Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Jean-Paul Kress$65,027,569———
Sandesh Mahatme39,406,098———
Qing Zuraw11,837,193———
Robert Ang3,364,3952,220,349—↑ +1,144,046

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Vor Biopharma's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper VOR reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against VOR
2 companies name VOR as a compensation peer

Each company listed discloses VOR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named VOR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Alexander (Bo) CumboIndependent Director$121,365
Andrew LevinIndependent Director$31,881
Daniella BeckmanIndependent Director$64,200
David LubnerFormer director (through FY2025)$35,307
Erez KalirIndependent Director$123,033
Fouad NamouniIndependent Director$51,089
Joshua ResnickFormer director (through FY2025)$38,765
Matthew PattersonFormer director (through FY2025)$57,574
Michel DetheuxIndependent Director$119,350
Sarah ReedFormer director (through FY2025)$105,208
Sven (Bill) Ante LundbergFormer director (through FY2025)$31,510
Wouter JoustraIndependent Director$31,881
02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Qing ZurawRSU46,854—$612,850
Robert AngOption7,00238.08—
Robert AngOption8,62599.4—
Robert AngOption12,874111—
Robert AngOption7,36443.52—
Qing ZurawOption218,65247.6—
Robert AngOption2,552360—
Jean-Paul KressOption4,164,83117.8—
Robert AngOption18,799172.6—
Robert AngOption106,33286.02—
Robert AngOption22,66148.2—
Robert AngOption41,24926.8—
Sandesh MahatmeOption1,388,27417.8—
05

Incentive-plan design — the Compensation Discussion & Analysis

A core objective of our compensation program is to enable the attraction, retention, and motivation of top talent that will provide us with the expertise and skills necessary to deliver on our short- and long-term goals. We consider compensation for comparable positions at peer companies, historical compensation levels, individual performance, and our desire to motivate employees to achieve short- and long-term results in the best interests of stockholders.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantAlpine Rewards, LLC
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Erez KalirIndependent · Audit · Partial-year service$42,033—$81,000——$123,033
Alexander (Bo) CumboIndependent · Compensation (Chair) · Nominating and Corporate Governance · Partial-year service22,973—98,392——121,365
Michel DetheuxIndependent · Audit · Partial-year service20,958—98,392——119,350
Sarah ReedIndependent · Departed during FY · Partial-year service13,283—91,925——105,208
Daniella BeckmanIndependent · Lead Independent Director · Audit (Chair) · Compensation60,000—4,200——64,200
Matthew PattersonIndependent · Departed during FY53,374—4,200——57,574
Fouad NamouniIndependent · Compensation · Nominating and Corporate Governance (Chair) · Partial-year service · Newly elected46,889—4,200——51,089
Joshua ResnickIndependent · Departed during FY · Partial-year service34,565—4,200——38,765
David LubnerIndependent · Departed during FY31,107—4,200——35,307
Wouter JoustraIndependent · Partial-year service1,522—30,359——31,881
Andrew LevinIndependent · Partial-year service · Newly elected1,522—30,359——31,881
Sven (Bill) Ante LundbergIndependent · Departed during FY · Partial-year service27,310—4,200——31,510
Robert AngEmployee director · Departed during FY—————0
Jean-Paul KressEmployee director · Board Chair · Partial-year service—————0
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)15,000 / 10,000 / 8,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$355,536
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$355,536

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Vor Biopharma2025Jean-Paul Kress$344,615$0$64,013,465$251,425$65,027,569

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Vor Biopharma in fiscal 2025?
As disclosed, Jean-Paul Kress (President, Chief Executive Officer and Chairman) was the highest-paid executive at Vor Biopharma in fiscal 2025, with total compensation of $65,027,569.
How much does Vor Biopharma spend in total on board compensation for fiscal 2025?
As disclosed, Vor Biopharma reported total board compensation of $355,536 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Jean-Paul KressDEF 14A2026-04-270001193125-26-181883Section “Executive Compensation”. As printed: 65,027,569. Filing ↗machine: r2 · c28 · span 644794–644804
2Section 01, Sandesh MahatmeDEF 14A2026-04-270001193125-26-181883Section “Executive Compensation”. As printed: 39,406,098. Filing ↗machine: span 685941–685951
3Section 01, Qing ZurawDEF 14A2026-04-270001193125-26-181883Section “Executive Compensation”. As printed: 11,837,193. Filing ↗machine: r8 · c28 · span 705218–705228
4Section 01, Robert AngDEF 14A2026-04-270001193125-26-181883Section “Executive Compensation”. As printed: 3,364,395. Filing ↗machine: r4 · c28 · span 664135–664144
5Section 08, Erez KalirDEF 14A2026-04-270001193125-26-181883Section “Director Compensation”. As printed: 123,033. Filing ↗machine: span 1016298–1016507
6Section 08, Alexander (Bo) CumboDEF 14A2026-04-270001193125-26-181883Section “Director Compensation”. As printed: 121,365. Filing ↗machine: span 1002196–1002405
7Section 08, Michel DetheuxDEF 14A2026-04-270001193125-26-181883Section “Director Compensation”. As printed: 119,350. Filing ↗machine: span 1006792–1007001
8Section 08, Sarah ReedDEF 14A2026-04-270001193125-26-181883Section “Director Compensation”. As printed: 105,208. Filing ↗machine: span 1040076–1040285
9Section 08, Daniella BeckmanDEF 14A2026-04-270001193125-26-181883Section “Director Compensation”. As printed: 64,200. Filing ↗machine: span 997595–997803
10Section 08, Matthew PattersonDEF 14A2026-04-270001193125-26-181883Section “Director Compensation”. As printed: 57,574. Filing ↗machine: span 1035325–1035533
11Section 08, Fouad NamouniDEF 14A2026-04-270001193125-26-181883Section “Director Compensation”. As printed: 51,089. Filing ↗machine: span 1049425–1049633
12Section 08, Joshua ResnickDEF 14A2026-04-270001193125-26-181883Section “Director Compensation”. As printed: 38,765. Filing ↗machine: span 1044832–1045040
13Section 08, David LubnerDEF 14A2026-04-270001193125-26-181883Section “Director Compensation”. As printed: 35,307. Filing ↗machine: span 1025803–1026011
14Section 08, Wouter JoustraDEF 14A2026-04-270001193125-26-181883Section “Director Compensation”. As printed: 31,881. Filing ↗machine: span 1011547–1011755
15Section 08, Andrew LevinDEF 14A2026-04-270001193125-26-181883Section “Director Compensation”. As printed: 31,881. Filing ↗machine: span 1021051–1021259
16Section 08, Sven (Bill) Ante LundbergDEF 14A2026-04-270001193125-26-181883Section “Director Compensation”. As printed: 31,510. Filing ↗machine: span 1030568–1030776
17Section 08, Robert AngDEF 14A2026-04-270001193125-26-181883Section “Director Compensation”. As printed: 0. Filing ↗
18Section 08, Jean-Paul KressDEF 14A2026-04-270001193125-26-181883Section “Director Compensation”. As printed: 0. Filing ↗
19Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
20Section 09b board cost (computed)Computed——Cash 355,536 + equity 0 + all other 0 = 355,536, summed across the director compensation table rows.machine: formula: Σ = 355,536
21Vor Biopharma (subject), Section 10b CEO totalDEF 14A2026-04-270001193125-26-181883CEO total compensation as printed in Vor Biopharma's own proxy. As printed: 65,027,569. Filing ↗machine: r2 · c28 · span 644794–644804

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.